Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Olink acquried by Thermo Fisher at nearly 75% premium following earlier deal rumors

EditorHari Govind
Published 17/10/2023, 15:30
© Reuters.

Shares of Olink Holding AB (NASDAQ:OLK) surged 66% higher Tuesday after the company agreed to be acquired by Thermo Fisher Scientific Inc. (NYSE:TMO) for $26 per ADS, or approximately $3.1 billion.

Today's news follows an exclusive StreetInsider.com report in August that Olink hired investment bank JP Morgan to explore a potential sale.

The takeover comes at an approximately 74% premium to Olink’s closing price on Monday.

Olink seeks to advance proteomics across various diseases and offers a broad portfolio of flexible protein biomarker solutions and library of high quality, thoroughly validated assays that cover ~3000 proteins.

Thermo Fisher expects Olink to deliver $200 million in revenue in 2024 and grow mid-teens organically. In the first, Thermo Fisher expects the transaction to be dilutive to EPS by $0.17, but excluding financing costs and non-cash deal-related equity compensation costs, the transaction is expected to be accretive by $0.10.

J.P. Morgan was the lead financial advisor for Olink. In addition, Goldman Sachs Bank Europe SE and Sweden Bankfilial served as financial advisors and Baker & McKenzie is serving as legal counsel for Olink. Cravath Swaine & Moore LLP and Advokatfirman Vinge KB were legal counsel for Thermo Fisher.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.